General Anesthesia Drugs Market
Market Insights on General Anesthesia Drugs covering sales outlook, demand forecast & up-to-date key trends
General Anesthesia Drugs Market by Drug Class, Route of Administration, End User & Region | Forecast 2022 to 2032
General Anesthesia Drugs Market Snapshot (2022 to 2032)
[182 Pages Report] The general anesthesia drugs market is expected to enjoy a valuation of US$ 4.7 Billion by the end of the year 2022, and further expand at a CAGR rate of 3.4% to reach a valuation of US$ 6.7 Billion by the year 2032. According to a recent study by Future Market Insights, the Propofol drug class is leading the market with a share of about 25.6% in the year 2021, within the global market.
Market Outlook:
|
Data Points |
Market Insights |
|
Market Value 2021 |
US$ 4.6 Billion |
|
Market Value 2022 |
US$ 4.7 Billion |
|
Market Value 2032 |
US$ 6.7 Billion |
|
CAGR 2022 to 2032 |
3.4% |
|
Market Share of Top 5 Countries |
63.4% |
|
Key Market Players |
Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KgaA, Pfizer, Hospira Inc., Aspen Pharmacare Holdings Limited, Hikama Pharmaceuticals plc, Abbott Laboratories, Avet Pharmaceuticals, Inc, Piramal Enterprises Limited, Par Pharmaceutical, Teva Pharmaceuticals, Viatris/Mylan, Novartis AG, GlaxoSmithKline plc, Gilead Sciences, Inc., Sanofi, Akorn, Apotex, Heritage Pharmaceuticals Inc. |
The market for general anesthesia drugs is expected to develop as a result of the widespread use of these drugs in various surgeries as well as the rise in cardiovascular disease and other disorders. The market for general anesthesia drugs is projected to expand due to the development of specific targeted drugs and the availability of technologically advanced drug delivery.
Let us know your requirement to get
100% FREE customization
Sales Analysis of General Anesthesia Drugs Market from 2014 to 2021 Vs Market Outlook for 2022 to 2032
The market value for general anesthesia drugs is approximately 69.1% of the overall US$ 6.7 Billion global anesthesia drug market in 2021.
The sale of general anesthesia drugs expanded at a CAGR of 3.2% from 2014 to 2021, owing to the Increasing prevalence of CRD and CVD.
The objective of general anesthesia is to cause analgesia, autonomic nervous system responses (ANS), and loss of consciousness. General anesthesia drugs injected intravenously are categorized as an IV anesthetic and are used to induce short surgical procedures.
The prevalence of co-morbidities among older people increases the risk of surgical issues and toxicities associated with general anesthesia will increase the sale of general anesthesia drugs in the forecasting period.
Drugs used for general anesthesia affect the effectiveness and cost of care in these outpatient settings. Hence, the general anesthesia drugs market is expected to expand in the projected period.
Manufacturers are focused on developing novel aesthetic drugs to sustain in the market. Additionally, manufacturers often engage in collaboration agreements and various licensing to assure the global accessibility of their products.
What are the Key Opportunities for the General Anesthesia Drugs Manufacturers?
An increase in the geriatric population is associated with an increase in chronic diseases that often require surgeries. For instance, as per the report published by World Health Organization on 4 October 2021, one in six individuals on the earth will be 60 or older by 2030. At this point, there will be 1.4 billion people over the age of 60, up from 1 billion in 2020. Thus, with an increasing old-age population, a larger number of surgeries are performed and there is high demand for anesthesia drugs.
The cost of healthcare expenditure is increasing in developing and developed countries. Anesthesia is generally covered by health insurance for all medical procedures. For patients with medical insurance, the out-of-pocket cost for anesthesia is around 10% to 50%. Thus, health insurance is beneficial for the management of anesthesia.
Ambulatory anesthesia offers quick recovery from general anesthesia drugs, patients can leave the hospital earlier while also offering massive benefits to third-party payers, hospitals, healthcare providers, and patients. Furthermore, due to ongoing advancements in general anesthesia drugs and various techniques, as well as the widespread availability of short-acting anesthetics with few side effects, the number of ambulatory surgeries has been rising exponentially.
Additionally, the market for general anesthesia drugs is projected to expand due to the development of specific targeted drugs and the availability of technologically sophisticated drug delivery devices.
Furthermore, the market for general anesthesia drugs is anticipated to generate significant revenue due to the number of clinical trials for the development of general anesthesia drugs and expanding portfolio of general anesthesia drugs and specific indications.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Factors Restraining Demand for General Anesthesia Drugs?
Side effects of drugs continue to include amnesia, respiratory depression, elevation in blood pressure and heart rate, and even hallucinations. For instance, drowsiness, vomiting and post-surgery nausea associated with opioid-containing anesthesia make it more difficult for the patient to recover. This restraining factor will hinder the market expansion of the general anesthesia drugs market in the future.
Post-surgery Effects of anesthesia drugs after surgery the recovery time is very critical as the patient may suffer some irreversible physical damage. Hence, patients are kept under clinical observation until consciousness is recovered.
Vomiting, nausea, irregularity in heart rhythm, body temperature, respiratory rate, sore throat, and irritation in the respiratory system are among the major shortcomings associated with general anesthesia drugs which badly impact the market.
Complications arising from general anesthetic drugs can be extensive, ranging from allergic reactions to the inefficacy of drugs. Although fatal complications are rare, common complications such as allergic reactions, cardiovascular collapse, drug interactions, prolonged apnoea, respiratory depression, jaundice, and anesthesia awareness are likely to occur while surgery.
Country-wise Insights
What Makes the USA a Highly Lucrative Market for General Anesthesia Drugs?
The USA holds approximately 95.5% share in the North American general anesthesia drugs market in 2021 and is projected to display growth at a lucrative CAGR rate of 2.4% during the forecast period.
In the USA plastic surgery is common in adults, especially in women. The USA is the highest country in terms of plastic and cosmetic surgeries. Furthermore, plastic surgeries further required general anesthesia drugs while surgery will boost the market expansion of genres of anesthesia drugs in the country. Over 15 million cosmetic surgery treatments are performed annually in the USA. For instance, according to, the Cleveland Clinic adults between the ages of 40 and 54 are more likely to have plastic surgeries, especially, since 92% of cosmetic surgery patients are women.
What Makes China a Large Market for General Anesthesia Drugs?
China is the second largest economic country with a market share of 18% in the global market in 2021.
In china cancer cases are rising globally will be a further need for general anesthesia drugs for treatment. For instance, report published by the National Library of Medicine, on 9 February 2022, In China, there will be 3,210,000 cancer fatalities and 4,820,000 new cancer cases in 2022.
What is the Outlook of Germany in the General Anesthesia Drugs Market?
Germany holds approximately 22% share of the European market in 2021 and is projected to display growth at a lucrative CAGR rate during the forecast period.
Factors influencing the expansion of general anesthetic medications in Germany are rapid growth in the geriatric population, rising prevalence of chronic diseases, and increasing healthcare expenditure. For instance, in a report published by Statista on 27 July 2022, The largest age group in Germany, with 23 million individuals, is 40 to 59. And 18.44 million people aged 65 and beyond made up the next-largest age group.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-wise Insights
Which General Anesthesia Drugs Class is Driving Market Growth?
The Propofol drug class is leading the market with a share of about 25.6% in the year 2021, with a CAGR of about 4.2% in the global market.
Propofol is an anesthetic agent used intravenously for the maintenance and induction of general anesthesia. It is used to induce unconsciousness. It is also used for the management of refractory status epileptics.
Which Route of Administration is more focussed within General Anesthesia Drugs Market Globally?
Intravenous holds a revenue share of 64.3% in 2021 and is expected to display gradual growth over the forecast period, with a CAGR of 3.6% by 2032. The drugs are directly administered to the systemic circulation via an intravenous route. When quick absorption is required, IV injections, which involve administering medication into the veins using a needle, are utilized.
Which End User Benefits the Most from the Sales of General Anesthesia Drugs Globally?
Hospitals hold a revenue share of 44.0% in 2021 and are expected to display gradual growth over the forecast period, with a CAGR of 3.8%. The high patient volume in hospitals and the rising number of procedures carried out in these settings can increase the market segment's growth. Surgeons in the hospitals have authority from the government to use anesthesia drugs and it is safe for the patients as they are under the observation of health workers.
Competitive Landscape
With several competitors in the general anesthesia drugs production sphere, the overall market is highly fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.
- On June 2019, PAION AG announced that The European Investment Bank would be providing it with capital in the amount of about $20 million.
- On 8 October 2020, Fresenius Kabi launched its first product with an RFID smart label In the U.S. The company's first smart-labeled product is the anesthetic Diprivan® (Propofol) injection, which comes in a 20 mL bottle and uses radio frequency identification (RFID) technology.
Similarly, recent developments related to companies manufacturing general anesthesia drugs have been tracked by the team at Future Market Insights, which are available in the full report.
Report Scope as per Industry Analysis
|
Attribute |
Details |
|
Forecast Period |
2014 to 2021 |
|
Historical Data Available for |
2022 to 2032 |
|
Market Analysis |
US$ Billion for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa (MEA) |
|
Key Countries Covered |
The USA, Canada, Brazil, Mexico, Argentina, The UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, South Africa |
|
Key Market Segments Covered |
Drug Class, Route of Administration, End User, and Region |
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Market Segments Covered in General Anesthesia Drugs Industry Research
By Drug Class:
- Propofol
- Sevoflurane
- Dexmedetomidine
- Desflurane
- Remifentanil
- Midazolam
- Others – (Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental etc.)
By Route of Administration:
- Intravenous Anesthesia
- Inhaled Anesthesia
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Frequently Asked Questions
How much is the general anesthesia drugs market worth in 2021?
The global general anesthesia drugs market is worth around US$ 4.6 Billion in 2021 and is expected to present high growth at a CAGR rate of 3.4% by the end of the forecast period.
What is the sales forecast for the general anesthesia drugs market through 2032?
The general anesthesia drugs market is expected to reach US$ 6.7 Billion by the end of 2032, with sales revenue anticipated to grow at 3.4% CAGR.
Which are the top 5 countries driving demand for general anesthesia drugs?
The USA, China, the UK, Japan, and Germany are expected to drive demand for the general anesthesia drugs industry.
Who are the key players in the general anesthesia drugs?
Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KgaA, Pfizer, Hospira Inc., Aspen Pharmacare Holdings Limited are some of the key players within the general anesthesia drugs market space.
Who are the key producers in the general anesthesia drugs?
General anesthesia drugs are mostly produced in the USA and China. This region's market expands more rapidly than the rest of the world.
What is the North American market outlook for general anesthesia drugs?
One of the major markets for general anesthesia drugs in North America, with a market share of about 29.6% in the year 2021.
What are the key trends shaping the general anesthesia drugs industry?
An increase in the incidence of CVD, CRD, accidents, and emergency surgeries an increase in research and development by the manufacturers, good product stability, and specificity are some of the key trends in the general anesthesia drugs market.
What was the last 10 years’ CAGR value growth for the general anesthesia drugs market?
From 2012 to 2021, the general anesthesia drugs market expanded at the rate of 3.2%.
How likely is the general anesthesia drugs market to grow in Japan?
Japan accounts for about 25.1% of the market share in 2021 in the East Asian general anesthesia drugs market.
At what percentage is the demand for general anesthesia drugs expected to register growth in Europe?
Demand for general anesthesia drugs in Europe is expected to register a growth of 3.0% over the next ten years
Table of Content
1. Executive Summary | General Anesthesia Drugs Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage/ Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Development/Innovation Trends 4. Key Success Factors 4.1. Product Adoption / Usage Analysis 4.2. New Product Launches 4.3. PESTEL Analysis 4.4. Porter’s Analysis 4.5. Drug Class Features/ USPs 4.6. Key Promotional Strategies, By Key Manufacturers 4.7. Regulatory Landscape 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure 5.1.3. Global Anesthesia Market 5.2. Forecast Factors - Relevance & Impact 5.2.1. Key Player’s Historic Growth 5.2.2. Market Consolidation Activities 5.2.3. New Product Launches / Approvals 5.2.4. Increasing Demand for General Anesthesia Drugs 5.2.5. Increasing Awareness Among People 5.2.6. Increase in the incidence of CVD, CRD, and Accidents. 5.2.7. Rising Geriatric Population 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis - Impact Assessment 6.1. COVID-19 and Impact Analysis 6.1.1. By Drug Class 6.1.2. By Route of Administration 6.1.3. By End User 6.1.4. By Region 6.2. 2021 Market Scenario 7. Global Market Demand Value or Size (US$ Million) Analysis 2014 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2014 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2032, By Drug Class 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2014 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2022 to 2032 8.3.1. Propofol 8.3.2. Sevoflurane 8.3.3. Dexmedetomidine 8.3.4. Desflurane 8.3.5. Remifentanil 8.3.6. Midazolam 8.3.7. Others 8.3.8. Others - Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental, etc.) 8.4. Market Attractiveness Analysis By Drug Class 9. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2032, By Route of Administration 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) By Route of Administration, 2014 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032 9.3.1. Intravenous Anesthesia 9.3.2. Inhaled Anesthesia 9.4. Market Attractiveness Analysis By Drug Class 10. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2032, By End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) By End User, 2014 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2032 10.3.1. Hospitals 10.3.2. Ambulatory Surgical Centers 10.3.3. Specialty Clinics 10.4. Market Attractiveness Analysis By End User 11. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2032, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Trend Analysis by Region, 2014 to 2021 11.3. Current and Future Market Size (US$ Million) and Forecast by Region, 2022 to 2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2014 to 2021 and Forecast 2022 to 2032 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2022 to 2032 12.3.1. By Country 12.3.1.1. The USA 12.3.1.2. Canada 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Drug Class 12.4.3. By Route of Administration 12.4.4. By End User 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country-Level Analysis & Forecast 12.8.1. U.S. Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Drug Class 12.8.1.2.2. By Route of Administration 12.8.1.2.3. By End User 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Drug Class 12.8.2.2.2. By Route of Administration 12.8.2.2.3. By End User 13. Latin America Market Analysis 2014 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2022 to 2032 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Class 13.4.3. By Route of Administration 13.4.4. By End User 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country-Level Analysis & Forecast 13.8.1. Mexico Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Drug Class 13.8.1.2.2. By Route of Administration 13.8.1.2.3. By End User 13.8.2. Brazil Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Drug Class 13.8.2.2.2. By Route of Administration 13.8.2.2.3. By End User 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Drug Class 13.8.3.2.2. By Route of Administration 13.8.3.2.3. By End User 14. Europe Market Analysis 2014 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2022 to 2032 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. The UK 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Class 14.4.3. By Route of Administration 14.4.4. By End User 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country-Level Analysis & Forecast 14.8.1. Germany Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Drug Class 14.8.1.2.2. By Route of Administration 14.8.1.2.3. By End User 14.8.2. Italy Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Drug Class 14.8.2.2.2. By Route of Administration 14.8.2.2.3. By End User 14.8.3. France Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Drug Class 14.8.3.2.2. By Route of Administration 14.8.3.2.3. By End User 14.8.4. The UK Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Drug Class 14.8.4.2.2. By Route of Administration 14.8.4.2.3. By End User 14.8.5. Spain Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Drug Class 14.8.5.2.2. By Route of Administration 14.8.5.2.3. By End User 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Drug Class 14.8.6.2.2. By Route of Administration 14.8.6.2.3. By End User 14.8.7. Russia Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Drug Class 14.8.7.2.2. By Route of Administration 14.8.7.2.3. By End User 15. East Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2022 to 2032 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Class 15.4.3. By Route of Administration 15.4.4. By End User 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country-Level Analysis & Forecast 15.8.1. China Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Drug Class 15.8.1.2.2. By Route of Administration 15.8.1.2.3. By End User 15.8.2. Japan Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Drug Class 15.8.2.2.2. By Route of Administration 15.8.2.2.3. By End User 15.8.3. South Korea Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Drug Class 15.8.3.2.2. By Route of Administration 15.8.3.2.3. By End User 16. South Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend by Market Taxonomy, 2014 to 2021 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2022 to 2032 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Indonesia 16.3.1.3. Malaysia 16.3.1.4. Thailand 16.3.1.5. Rest of South Asia 16.3.2. By Drug Class 16.3.3. By Route of Administration 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Class 16.4.3. By Route of Administration 16.4.4. By End User ; 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country-Level Analysis & Forecast 16.8.1. India Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Drug Class 16.8.1.2.2. By Route of Administration 16.8.1.2.3. By End User 16.8.2. Indonesia Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Drug Class 16.8.2.2.2. By Route of Administration 16.8.2.2.3. By End User 16.8.3. Malaysia Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Drug Class 16.8.3.2.2. By Route of Administration 16.8.3.2.3. By End User 16.8.4. Thailand Market Analysis 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast by Market Taxonomy 16.8.4.2.1. By Drug Class 16.8.4.2.2. By Route of Administration 16.8.4.2.3. By End User 17. Oceania Market 2014-2021 and Forecast 2022-2032 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2022 to 2032 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Class 17.4.3. By Route of Administration 17.4.4. By End User 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country-Level Analysis & Forecast 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Drug Class 17.8.1.2.2. By Route of Administration 17.8.1.2.3. By End User 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Drug Class 17.8.2.2.2. By Route of Administration 17.8.2.2.3. By End User 18. Middle East and Africa (MEA) Market Analysis 2014 to 2021 and Forecast 2022 to 2032 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2022 to 2032 18.3.1. ;By Country 18.3.1.1. GCC Countries 18.3.1.2. Turkey 18.3.1.3. South Africa 18.3.1.4. North Africa 18.3.1.5. Rest of Middle East and Africa 18.3.2. By Drug Class 18.3.3. By Route of Administration 18.3.4. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug Class 18.4.3. By Route of Administration 18.4.4. By End User 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country-Level Analysis & Forecast 18.8.1. GCC Countries Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Drug Class 18.8.1.2.2. By Route of Administration 18.8.1.2.3. By End User 18.8.2. Turkey Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Drug Class 18.8.2.2.2. By Route of Administration 18.8.2.2.3. By End User 18.8.3. South Africa Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Drug Class 18.8.3.2.2. By Route of Administration 18.8.3.2.3. By End Use 18.8.4. North Africa Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Drug Class 18.8.4.2.2. By Route of Administration 18.8.4.2.3. By End User 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players (%) 19.3. Market Presence Analysis 19.3.1. By Regional Footprint of Players 19.3.2. Product Footprint of Players 19.3.3. Channel Footprint of Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Baxter International Inc. 20.3.1.1. Overview 20.3.1.2. Drug Class Portfolio 20.3.1.3. Key Financials 20.3.1.4. SWOT Analysis 20.3.1.5. Key Developments 20.3.1.6. Sales Footprint 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategy 20.3.1.7.2. Product Strategy 20.3.1.7.3. Channel Strategy 20.3.2. AstraZeneca 20.3.2.1. Overview 20.3.2.2. Drug Class Portfolio 20.3.2.3. Key Financials 20.3.2.4. SWOT Analysis 20.3.2.5. Key Developments 20.3.2.6. Sales Footprint 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategy 20.3.2.7.2. Product Strategy 20.3.2.7.3. Channel Strategy 20.3.3. AbbVie Inc. 20.3.3.1. Overview 20.3.3.2. Drug Class Portfolio 20.3.3.3. Key Financials 20.3.3.4. SWOT Analysis 20.3.3.5. Key Developments 20.3.3.6. Sales Footprint 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategy 20.3.3.7.2. Product Strategy 20.3.3.7.3. Channel Strategy 20.3.4. B. Braun Melsungen AG 20.3.4.1. Overview 20.3.4.2. Drug Class Portfolio 20.3.4.3. Key Financials 20.3.4.4. SWOT Analysis 20.3.4.5. Key Developments 20.3.4.6. Sales Footprint 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategy 20.3.4.7.2. Product Strategy 20.3.4.7.3. Channel Strategy 20.3.5. Fresenius SE & Co. KgaA 20.3.5.1. Overview 20.3.5.2. Drug Class Portfolio 20.3.5.3. Key Financials 20.3.5.4. SWOT Analysis 20.3.5.5. Key Developments 20.3.5.6. Sales Footprint 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategy 20.3.5.7.2. Product Strategy 20.3.5.7.3. Channel Strategy 20.3.6. Pfizer 20.3.6.1. Overview 20.3.6.2. Drug Class Portfolio 20.3.6.3. Key Financials 20.3.6.4. SWOT Analysis 20.3.6.5. Key Developments 20.3.6.6. Sales Footprint 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategy 20.3.6.7.2. Product Strategy 20.3.6.7.3. Channel Strategy 20.3.7. Hospira Inc. 20.3.7.1. Overview 20.3.7.2. Drug Class Portfolio 20.3.7.3. Key Financials 20.3.7.4. SWOT Analysis 20.3.7.5. Key Developments 20.3.7.6. Sales Footprint 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategy 20.3.7.7.2. Product Strategy 20.3.7.7.3. Channel Strategy 20.3.8. Aspen Pharmacare Holdings Limited 20.3.8.1. Overview 20.3.8.2. Drug Class Portfolio 20.3.8.3. Key Financials 20.3.8.4. SWOT Analysis 20.3.8.5. Key Developments 20.3.8.6. Sales Footprint 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategy 20.3.8.7.2. Product Strategy 20.3.8.7.3. Channel Strategy 20.3.9. Hikama Pharmaceuticals plc 20.3.9.1. Overview 20.3.9.2. Drug Class Portfolio 20.3.9.3. Key Financials 20.3.9.4. SWOT Analysis 20.3.9.5. Key Developments 20.3.9.6. Sales Footprint 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategy 20.3.9.7.2. Product Strategy 20.3.9.7.3. Channel Strategy 20.3.10. Abbott Laboratories 20.3.10.1. Overview 20.3.10.2. Drug Class Portfolio 20.3.10.3. Key Financials 20.3.10.4. SWOT Analysis 20.3.10.5. Key Developments 20.3.10.6. Sales Footprint 20.3.10.7. Strategy Overview 20.3.10.7.1. Marketing Strategy 20.3.10.7.2. Product Strategy 20.3.10.7.3. Channel Strategy 20.3.11. Avet Pharmaceuticals, Inc 20.3.11.1. Overview 20.3.11.2. Drug Class Portfolio 20.3.11.3. Key Financials 20.3.11.4. SWOT Analysis 20.3.11.5. Key Developments 20.3.11.6. Sales Footprint 20.3.11.7. Strategy Overview 20.3.11.7.1. Marketing Strategy 20.3.11.7.2. Product Strategy 20.3.11.7.3. Channel Strategy 20.3.12. Piramal Enterprises Limited 20.3.12.1. Overview 20.3.12.2. Drug Class Portfolio 20.3.12.3. Key Financials 20.3.12.4. SWOT Analysis 20.3.12.5. Key Developments 20.3.12.6. Sales Footprint 20.3.12.7. Strategy Overview 20.3.12.7.1. Marketing Strategy 20.3.12.7.2. Product Strategy 20.3.12.7.3. Channel Strategy 20.3.13. Par Pharmaceutical 20.3.13.1. Overview 20.3.13.2. Drug Class Portfolio 20.3.13.3. Key Financials 20.3.13.4. SWOT Analysis 20.3.13.5. Key Developments 20.3.13.6. Sales Footprint 20.3.13.7. Strategy Overview 20.3.13.7.1. Marketing Strategy 20.3.13.7.2. Product Strategy 20.3.13.7.3. Channel Strategy 20.3.14. Teva Pharmaceuticals 20.3.14.1. Overview 20.3.14.2. Drug Class Portfolio 20.3.14.3. Key Financials 20.3.14.4. SWOT Analysis 20.3.14.5. Key Developments 20.3.14.6. Sales Footprint 20.3.14.7. Strategy Overview 20.3.14.7.1. Marketing Strategy 20.3.14.7.2. Product Strategy 20.3.14.7.3. Channel Strategy 20.3.15. Viatris/Mylan 20.3.15.1. Overview 20.3.15.2. Drug Class Portfolio 20.3.15.3. Key Financials 20.3.15.4. SWOT Analysis 20.3.15.5. Key Developments 20.3.15.6. Sales Footprint 20.3.15.7. Strategy Overview 20.3.15.7.1. Marketing Strategy 20.3.15.7.2. Product Strategy 20.3.15.7.3. Channel Strategy 20.3.16. Novartis AG 20.3.16.1. Overview 20.3.16.2. Drug Class Portfolio 20.3.16.3. Key Financials 20.3.16.4. SWOT Analysis 20.3.16.5. Key Developments 20.3.16.6. Sales Footprint 20.3.16.7. Strategy Overview 20.3.16.7.1. Marketing Strategy 20.3.16.7.2. Product Strategy 20.3.16.7.3. Channel Strategy 20.3.17. GlaxoSmithKline plc 20.3.17.1. Overview 20.3.17.2. Drug Class Portfolio 20.3.17.3. Key Financials 20.3.17.4. SWOT Analysis 20.3.17.5. Key Developments 20.3.17.6. Sales Footprint 20.3.17.7. Strategy Overview 20.3.17.7.1. Marketing Strategy 20.3.17.7.2. Product Strategy 20.3.17.7.3. Channel Strategy 20.3.18. Gilead Sciences, Inc. 20.3.18.1. Overview 20.3.18.2. Drug Class Portfolio 20.3.18.3. Key Financials 20.3.18.4. SWOT Analysis 20.3.18.5. Key Developments 20.3.18.6. Sales Footprint 20.3.18.7. Strategy Overview 20.3.18.7.1. Marketing Strategy 20.3.18.7.2. Product Strategy 20.3.18.7.3. Channel Strategy 20.3.19. Sanofi 20.3.19.1. Overview 20.3.19.2. Drug Class Portfolio 20.3.19.3. Key Financials 20.3.19.4. SWOT Analysis 20.3.19.5. Key Developments 20.3.19.6. Sales Footprint 20.3.19.7. Strategy Overview 20.3.19.7.1. Marketing Strategy 20.3.19.7.2. Product Strategy 20.3.19.7.3. Channel Strategy 20.3.20. Akorn 20.3.20.1. Overview 20.3.20.2. Drug Class Portfolio 20.3.20.3. Key Financials 20.3.20.4. SWOT Analysis 20.3.20.5. Key Developments 20.3.20.6. Sales Footprint 20.3.20.7. Strategy Overview 20.3.20.7.1. Marketing Strategy 20.3.20.7.2. Product Strategy 20.3.20.7.3. Channel Strategy 20.3.21. Apotex 20.3.21.1. Overview 20.3.21.2. Drug Class Portfolio 20.3.21.3. Key Financials 20.3.21.4. SWOT Analysis 20.3.21.5. Key Developments 20.3.21.6. Sales Footprint 20.3.21.7. Strategy Overview 20.3.21.7.1. Marketing Strategy 20.3.21.7.2. Product Strategy 20.3.21.7.3. Channel Strategy 20.3.22. Heritage Pharmaceuticals Inc. 20.3.22.1. Overview 20.3.22.2. Drug Class Portfolio 20.3.22.3. Key Financials 20.3.22.4. SWOT Analysis 20.3.22.5. Key Developments 20.3.22.6. Sales Footprint 20.3.22.7. Strategy Overview 20.3.22.7.1. Marketing Strategy 20.3.22.7.2. Product Strategy 20.3.22.7.3. Channel Strategy 21. Assumptions and Acronyms Used 22. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Analysis 2017–2021 and Forecast 2022–2032, By Drug Class Table 02: Global Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration Table 03: Global Market Analysis 2017–2021 and Forecast 2022–2032, By End User Table 04: Global Market Analysis 2017–2021 and Forecast 2022–2032, By Region Table 05: North America Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country Table 06: North America Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class Table 07: North America Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration Table 08: North America Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User Table 09: Latin America Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country Table 10: Latin America Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class Table 11: Latin America Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration Table 12: Latin America Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User Table 13: Europe Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country Table 14: Europe Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class Table 15: Europe Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration Table 16: Europe Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User Table 17: East Asia Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country Table 18: East Asia Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class Table 19: East Asia Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration Table 20: East Asia Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User Table 21: South Asia Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country Table 22: South Asia Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class Table 23: South Asia Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration Table 24: South Asia Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User Table 25: Oceania Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country Table 26: Oceania Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class Table 27: Oceania Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration Table 28: Oceania Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User Table 29: Middle East & Africa Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country Table 30: Middle East & Africa Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class Table 31: Middle East & Africa Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration Table 32: Middle East & Africa Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Value Analysis, 2017 to 2021 Figure 02: Global Market Forecast & Y-o-Y Growth, 2022 to 2032 Figure 03: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2021 to 2032 Figure 04: Global Market Value Share (%) Analysis 2022 and 2032, By Drug Class Figure 05: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, By Drug Class Figure 06: Global Market Attractiveness Analysis 2022 to 2032, By Drug Class Figure 07: Global Market Value Share (%) Analysis 2022 and 2032, By Route of Administration Figure 08: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, By Route of Administration Figure 09: Global Market Attractiveness Analysis 2022 to 2032, By Route of Administration Figure 10: Global Market Value Share (%) Analysis 2022 and 2032, By End User Figure 11: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, By End User Figure 12: Global Market Attractiveness Analysis 2022 to 2032, By End User Figure 13: Global Market Value Share (%) Analysis 2022 and 2032, By Region Figure 14: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, By Region Figure 15: Global Market Attractiveness Analysis 2022 to 2032, By Region Figure 16: North America Market Size (US$ Million) Analysis, 2022E to 2032F Figure 17: North America Market Y-o-Y Analysis, 2022 to 2032 Figure 18: North America Market Value Analysis, 2017 to 2021 Figure 19: North America Market Forecast & Y-o-Y growth, 2022 to 2032 Figure 20: North America Market Value Share, By Drug Class (2022 E) Figure 21: North America Market Value Share, By Route of Administration (2022 E) Figure 22: North America Market Value Share, By End User (2022 E) Figure 23: North America Market Value Share, By Country (2022 E) Figure 24: North America Market Attractiveness Analysis by Drug Class, 2022 to 2032 Figure 25: North America Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 26: North America Market Attractiveness Analysis by End User, 2022 to 2032 Figure 27: North America Market Attractiveness Analysis by Country, 2022 to 2032 Figure 28: U.S. Market Value Proportion Analysis, 2021 Figure 29: U.S. Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 30: U.S. Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 31: U.S. Market Share Analysis (%) By End User, 2021 to 2032 Figure 32: Global Vs. U.S. Growth Comparison Figure 33: Canada Market Value Proportion Analysis, 2021 Figure 34: Canada Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 35: Canada Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 36: Canada Market Share Analysis (%) By End User, 2021 to 2032 Figure 37: Global Vs. Canada. Growth Comparison Figure 38: Latin America Market Size (US$ Million) Analysis, 2022E to 2032F Figure 39: Latin America Market Y-o-Y Analysis, 2022 to 2032 Figure 40: Latin America Market Value Analysis, 2017 to 2021 Figure 41: Latin America Market Forecast & Y-o-Y growth, 2022 to 2032 Figure 42: Latin America Market Value Share, By Drug Class (2022 E) Figure 43: Latin America Market Value Share, By Route of Administration (2022 E) Figure 44: Latin America Market Value Share, By End User (2022 E) Figure 45: Latin America Market Value Share, By Country (2022 E) Figure 46: Latin America Market Attractiveness Analysis by Drug Class, 2022 to 2032 Figure 47: Latin America Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 48: Latin America Market Attractiveness Analysis by End User, 2022 to 2032 Figure 49: Latin America Market Attractiveness Analysis by Country, 2022 to 2032 Figure 50: Mexico Market Value Proportion Analysis, 2021 Figure 51: Mexico Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 52: Mexico Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 53: Mexico Market Share Analysis (%) By End User, 2021 to 2032 Figure 54: Global Vs Mexico Growth Comparison Figure 55: Brazil Market Value Proportion Analysis, 2021 Figure 56: Brazil Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 57: Brazil Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 58: Brazil Market Share Analysis (%) By End User, 2021 to 2032 Figure 59: Global Vs. Brazil. Growth Comparison Figure 60: Argentina Market Value Proportion Analysis, 2021 Figure 61: Argentina Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 62: Argentina Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 63: Argentina Market Share Analysis (%) By End User, 2021 to 2032 Figure 64: Global Vs Argentina Growth Comparison Figure 65: Europe Market Size (US$ Million) Analysis, 2022E to 2032F Figure 66: Europe Market Y-o-Y Analysis, 2022 to 2032 Figure 67: Europe Market Value Analysis, 2017 to 2021 Figure 68: Europe Market Forecast & Y-o-Y growth, 2022 to 2032 Figure 69: Europe Market Value Share, By Drug Class (2022 E) Figure 70: Europe Market Value Share, By Route of Administration (2022 E) Figure 71: Europe Market Value Share, By End User (2022 E) Figure 72: Europe Market Value Share, By Country (2022 E) Figure 73: Europe Market Attractiveness Analysis by Drug Class, 2022 to 2032 Figure 74: Europe Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 75: Europe Market Attractiveness Analysis by End User, 2022 to 2032 Figure 76: Europe Market Attractiveness Analysis by Country, 2022 to 2032 Figure 77: U.K. Market Value Proportion Analysis, 2021 Figure 78: U.K. Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 79: U.K. Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 80: U.K. Market Share Analysis (%) By End User, 2021 to 2032 Figure 81: Global Vs. U.K. Growth Comparison Figure 82: Germany Market Value Proportion Analysis, 2021 Figure 83: Germany Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 84: Germany Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 85: Germany Market Share Analysis (%) By End User, 2021 to 2032 Figure 86: Global Vs. Germany Growth Comparison Figure 87: Italy Market Value Proportion Analysis, 2021 Figure 88: Italy Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 89: Italy Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 90: Italy Market Share Analysis (%) By End User, 2021 to 2032 Figure 91: Global Vs. Italy Growth Comparison Figure 92: France Market Value Proportion Analysis, 2021 Figure 93: France Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 94: France Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 95: France Market Share Analysis (%) By End User, 2021 to 2032 Figure 96: Global Vs France Growth Comparison Figure 97: Spain Market Value Proportion Analysis, 2021 Figure 98: Spain Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 99: Spain Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 100: Spain Market Share Analysis (%) By End User, 2021 to 2032 Figure 101: Global Vs Spain Growth Comparison Figure 102: Russia Market Value Proportion Analysis, 2021 Figure 103: Russia Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 104: Russia Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 105: Russia Market Share Analysis (%) By End User, 2021 to 2032 Figure 106: Global Vs Russia Growth Comparison Figure 107: BENELUX Market Value Proportion Analysis, 2021 Figure 108: BENELUX Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 109: BENELUX Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 110: BENELUX Market Share Analysis (%) By End User, 2021 to 2032 Figure 111: Global Vs BENELUX Growth Comparison Figure 112: East Asia Market Size (US$ Million) Analysis, 2022E to 2032F Figure 113: East Asia Market Y-o-Y Analysis, 2022 to 2032 Figure 114: East Asia Market Value Analysis, 2017 to 2021 Figure 115: East Asia Market Forecast & Y-o-Y growth, 2022 to 2032 Figure 116: East Asia Market Value Share, By Drug Class (2022 E) Figure 117: East Asia Market Value Share, By Route of Administration (2022 E) Figure 118: East Asia Market Value Share, By End User (2022 E) Figure 119: East Asia Market Value Share, By Country (2022 E) Figure 120: East Asia Market Attractiveness Analysis by Drug Class, 2022 to 2032 Figure 121: East Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 122: East Asia Market Attractiveness Analysis by End User, 2022 to 2032 Figure 123: East Asia Market Attractiveness Analysis by Country, 2022 to 2032 Figure 124: China Market Value Proportion Analysis, 2021 Figure 125: China Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 126: China Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 127: China Market Share Analysis (%) By End User, 2021 to 2032 Figure 128: Global Vs. China Growth Comparison Figure 129: Japan Market Value Proportion Analysis, 2021 Figure 130: Japan Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 131: Japan Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 132: Japan Market Share Analysis (%) By End User, 2021 to 2032 Figure 133: Global Vs. Japan Growth Comparison Figure 134: South Korea Market Value Proportion Analysis, 2021 Figure 135: South Korea Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 136: South Korea Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 137: South Korea Market Share Analysis (%) By End User, 2021 to 2032 Figure 138: Global Vs South Korea Growth Comparison Figure 139: South Asia Market Size (US$ Million) Analysis, 2022E to 2032F Figure 140: South Asia Market Y-o-Y Analysis, 2022 to 2032 Figure 141: South Asia Market Value Analysis, 2017 to 2021 Figure 142: South Asia Market Forecast & Y-o-Y growth, 2022 to 2032 Figure 143: South Asia Market Value Share, By Drug Class (2022 E) Figure 144: South Asia Market Value Share, By Route of Administration (2022 E) Figure 145: South Asia Market Value Share, By End User (2022 E) Figure 146: South Asia Market Value Share, By Country (2022 E) Figure 147: South Asia Market Attractiveness Analysis by Drug Class, 2022 to 2032 Figure 148: South Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 149: South Asia Market Attractiveness Analysis by End User, 2022 to 2032 Figure 150: South Asia Market Attractiveness Analysis by Country, 2022 to 2032 Figure 151: India Market Value Proportion Analysis, 2021 Figure 152: India Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 153: India Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 154: India Market Share Analysis (%) By End User, 2021 to 2032 Figure 155: Global Vs. India Growth Comparison Figure 156: Indonesia Market Value Proportion Analysis, 2021 Figure 157: Indonesia Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 158: Indonesia Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 159: Indonesia Market Share Analysis (%) By End User, 2021 to 2032 Figure 160: Global Vs. Indonesia Growth Comparison Figure 161: Malaysia Market Value Proportion Analysis, 2021 Figure 162: Malaysia Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 163: Malaysia Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 164: Malaysia Market Share Analysis (%) By End User, 2021 to 2032 Figure 165: Global Vs. Malaysia Growth Comparison Figure 166: Thailand Market Value Proportion Analysis, 2021 Figure 167: Thailand Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 168: Thailand Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 169: Thailand Market Share Analysis (%) By End User, 2021 to 2032 Figure 170: Global Vs. Thailand Growth Comparison Figure 171: Oceania Market Size (US$ Million) Analysis, 2022E to 2032F Figure 172: Oceania Market Y-o-Y Analysis, 2022 to 2032 Figure 173: Oceania Market Value Analysis, 2017 to 2021 Figure 174: Oceania Market Forecast & Y-o-Y growth, 2022 to 2032 Figure 175: Oceania Market Value Share, By Drug Class (2022 E) Figure 176: Oceania Market Value Share, By Route of Administration (2022 E) Figure 177: Oceania Market Value Share, By End User (2022 E) Figure 178: Oceania Market Value Share, By Country (2022 E) Figure 179: Oceania Market Attractiveness Analysis by Drug Class, 2022 to 2032 Figure 180: Oceania Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 181: Oceania Market Attractiveness Analysis by End User, 2022 to 2032 Figure 182: Oceania Market Attractiveness Analysis by Country, 2022 to 2032 Figure 183: Australia Market Value Proportion Analysis, 2021 Figure 184: Australia Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 185: Australia Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 186: Australia Market Share Analysis (%) By End User, 2021 to 2032 Figure 187: Global Vs. Australia Growth Comparison Figure 188: New Zealand Market Value Proportion Analysis, 2021 Figure 189: New Zealand Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 190: New Zealand Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 191: New Zealand Market Share Analysis (%) By End User, 2021 to 2032 Figure 192: Global Vs New Zealand Growth Comparison Figure 193: Middle East & Africa Market Size (US$ Million) Analysis, 2022E to 2032F Figure 194: Middle East & Africa Market Y-o-Y Analysis, 2022 to 2032 Figure 195: Middle East & Africa Market Value Analysis, 2017 to 2021 Figure 196: Middle East & Africa Market Forecast & Y-o-Y growth, 2022 to 2032 Figure 197: Middle East & Africa Market Value Share, By Drug Class (2022 E) Figure 198: Middle East & Africa Market Value Share, By Route of Administration (2022 E) Figure 199: Middle East & Africa Market Value Share, By End User (2022 E) Figure 200: Middle East & Africa Market Value Share, By Country (2022 E) Figure 201: Middle East & Africa Market Attractiveness Analysis by Drug Class, 2022 to 2032 Figure 202: Middle East & Africa Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 203: Middle East & Africa Market Attractiveness Analysis by End User, 2022 to 2032 Figure 204: Middle East & Africa Market Attractiveness Analysis by Country, 2022 to 2032 Figure 205: GCC Countries Market Value Proportion Analysis, 2021 Figure 206: GCC Countries Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 207: GCC Countries Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 208: GCC Countries Market Share Analysis (%) By End User, 2021 to 2032 Figure 209: Global Vs GCC Countries Growth Comparison Figure 210: Turkey Market Value Proportion Analysis, 2021 Figure 211: Turkey Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 212: Turkey Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 213: Turkey Market Share Analysis (%) By End User, 2021 to 2032 Figure 214: Global Vs. Turkey Growth Comparison Figure 215: South Africa Market Value Proportion Analysis, 2021 Figure 216: South Africa Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 217: South Africa Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 218: South Africa Market Share Analysis (%) By End User, 2021 to 2032 Figure 219: Global Vs. South Africa Growth Comparison Figure 220: North Africa Market Value Proportion Analysis, 2021 Figure 221: North Africa Market Share Analysis (%) By Drug Class, 2021 to 2032 Figure 222: North Africa Market Share Analysis (%) By Route of Administration, 2021 to 2032 Figure 223: North Africa Market Share Analysis (%) By End User, 2021 to 2032 Figure 224: Global Vs North Africa Growth Comparison
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
